急性早幼粒细胞白血病中CD117和CD34共表达的临床意义  

The clinic significance of CD117/CD34 co-expression in the patients with acute promyelocytic leukemia

作　　者：时昊张日 肖爱琴[2] 张志[1] 朱锋[1] 

机构地区：[1]泰山医学院附属医院血液科,泰安271000 [2]苏州医学院附属第一医院血液科,苏州215006

出　　处：《中国免疫学杂志》2006年第6期576-578,共3页Chinese Journal of Immunology

基　　金：山东省教育厅科技计划项目(J05L09)

摘　　要：目的：研究CD117和CD34在成人急性非淋巴细胞自血病（Acute nonlymphoblastic leukemia，ANLL）M1～M2型和急性早幼粒细胞白血病（Acute promyelocytic leukemia，arE）M3患者中的表达，重点探讨M3患者CD117和CD34共表达（CD117／CD34共表达）的临床意义。方法：将研究病例分为M1～M2和M3二组，采用流式细胞术（Flow cytometery，FCM）随机检测54例M3和63例M1～M2二组初诊患者骨髓单个核细胞（BMMNC）髓系抗原CD117和干（祖）细胞抗原CD34的表达；比较M1～M2和M3二组ANLL患者中CD117、CD34表达的阳性率的差异，以及CD13、CD33和CD117分别与CD34共表达的阳性率差异。结果：CD117在M1～M2组患者中表达的阳性率是71．4／％（45／63），在M3组表达的阳性率为66．7％（36／54），差异无统计学意义（P=0．58）；CD34在M1～M2和M3二组中表达的阳性率分别为66．7％（42／63）和11．1％（6／54），差异有统计学意义（P=0．000）；二组ANLL的CD117／CD34共表达阳性率分别为71．1％（45／63）和7．4％（4／54），其差异有统计学意义（P=0．000）。结论：CD117可作为AL的髓系免疫学标志，但其在ANLL中的表达缺乏系列内阶段特异性。M3患者的CD34表达和CD117／CD34共表达的阳性率低于M1～M2者；CD117／CD34共表达可作为M1～M2和M3鉴别诊断的免疫学分型参考指标。Objective：To study expressions of CD117 and CD34 in the patients with acute promyelocytic leukemia（ APL, M3） and in M1-M2 subtype from FAB classification for acute leukemia（AL）. The focus of the study would be laid on the chnical significance of CDl17/CD34 co-expression in the patients of M3 subtype. Methods： Researched cases of acute nonlymphoblastic leukemia （ANLL） were divided into two groups ：M1-M2 subtype and M3 subtype . Flow cytometery（FCM） was used to detect the rates of positive expression of CD117 and CD34 on bone marrow mononuclear cell（BMMNC） in 54 patients of M3 and 63 patients of M1-M2 subtype respectively. Meanwhile, we compared the differences between the rates of expression of CD117 and CD 34. And, the rates of CD117/CD34 co-expression in patients of M1-M2 subtype and M3 subtype were studied. Results：Our results revealed that the positive rates of CD117 expression in M1-M2 subtype and M3 subtype were 71.4% （45/63） and 66. 7% （36/54） respectively（ P = 0.58）. The positive rates of CD34 expression in M1-M2 subtype and M3 subtype were 66. 7% （42/63） and 11.1% （6/54） respectively（P = 0. 000）. The positive rates of CD117/CD34 co-expression in M1-M2 subtype and M3 subtype were 71.1% （45/63） and 7.4% （4/54） respectively（ P = 0. 000）. Condusion：CD117 may be used as immunology marker for leukemia of myeloid origin. CD34 had lower expression in M3 subtype than in M1-M2 subtype. The positive rate of CD117/CD34 co-expression in M3 subtype was significantly lower than that in M1-M2 subtype, which can help for diagnosis of M3 subtype and help differentiate M3 subtype from M1-M2 subtype as well.

关 键 词：急性早幼粒细胞白血病 抗原CD117 抗原CD34 共表达 急性非淋巴细胞白血病 

分 类 号：R733.71[医药卫生—肿瘤]